📰 Immunic News
Page 13 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
February 24, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
February 18, 2022
DGAP-News: Immunic, Inc. / Key word(s): Conference/Study results Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics
February 17, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
February 17, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
February 10, 2022
Capital increase in cash via an accelerated book building procedure for an amount of approximately €3.5 m MUNIC (Euronext Growth® Paris - FR0013462231 - ALMUN), specialist in embedded and artificial
February 8, 2022
DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in Investor and Scientific Conferences in February 08.02.2022 / 12:30 The issuer is solely responsible
February 8, 2022
DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in Investor and Scientific Conferences in February 08.02.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Investor and Scientific Conferences in Febr...
February 8, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at...
February 8, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at...
February 2, 2022
DGAP-News: Immunic, Inc. / Key word(s): Patent Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class